** Drug developer NKGen Biotech's shares NKGN.O surge 26% to 47 cents
** Company says U.S. FDA has granted "fast track" designation for its experimental drug, troculeucel, for the treatment of moderate Alzheimer's disease, a neurodegenerative disorder that causes cognitive impairment
** The FDA's "fast track" program is designed to facilitate the development and expedite review of drug candidates that aim to treat serious conditions and fulfill an unmet medical need
** NKGN is also developing the drug as a treatment for other neurodegenerative disorders and a broad range of cancers
** Stock fell ~71% in the last 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.